Nadia Mannell
Angel Investor
Dubai, United Arab Emirates
Nadia Mannell is a seed investor in Dubai focused on Women's and mHealth. Nadia Mannell Founding General Partner of Seed South Capital.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nadia Mannell invests in
Stages Nadia Mannell invests in
Countries Nadia Mannell invests in
Investment Focus
Industry
- Women's 1 (100%)
- mHealth 1 (100%)
- Health Care 1 (100%)
- Personal Health 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nabta Health
|
Nabta’s unique model of hybrid healthcare seamlessly combines digital health with traditional healthcare to improve health outcomes in women living with NCDs.The growing epidemic of NCDs threatens the ambition of countries around the world to achieve sustainable, universal access to health and universal health coverage for their populations.Moreover, NCDs leave populations more susceptible to communicable diseases such as coronaviruses, influenza and tuberculosis. During the COVID-19 pandemic of 2020, 78% of people admitted to ICU in the US and 94% of those who died had underlying health conditions (CDC).NCDs remain underesearched and underserved in women. Until the mid-1990s, clinical research and clinical trials largely excluded women. Only since 1994, when the United States’ National Institutes of Health (NIH) mandated that women and minorities were to be included as subjects in clinical research, has the research community entertained the fact that sex and/or gender differences might affect clinical outcomes.Today, women using drugs that were approved by the early 90s, are 50–75% more likely than men to suffer adverse reactions to those therapies. Ironically, a significant proportion of the drugs in this category are those designed to treat or manage NCDs. Examples include statins and potassium channel-blockers used to manage cardiovascular disease or hypoglycaemic drugs such as Rezulin used to control diabetes.Nabta’s first hybrid care pathway supports women in preventing, identifying and managing Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal disorder responsible for 70% of female fertility issues. Women who use Nabta’s platform will be able to achieve a formal diagnosis of PCOS within 90 days. The average time taken to diagnose PCOS currently is 2.5 years. | $1.5M / Seed / Feb 22, 2022 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nadia Mannell invest in?
Nadia Mannell invests primarily in Women's, mHealth and Health Care startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United Arab Emirates. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nadia Mannell last invest?
The most recent investment recorded for Nadia Mannell closed in Feb 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
